All In Biotech

Drug Trial Radar · NCT07447817

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

May 24, 2030

Study completion May 24, 2030

Sponsor

Lead sponsor
John MascarenhasAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sobi, Inc.; Karyopharm Therapeutics Inc; National Cancer Institute (NCI)
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.

Conditions

  • Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Interventions

  • PacritinibDrug

    Pacritinib 200mg twice a day (BID) by mouth (PO)

  • SelinexorDrug

    Selinexor 60mg once weekly (QW) by mouth (PO)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in spleen volumeTime frame: Baseline and 24 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Kansas Cancer Center-Westwood

    Westwood, Kansas · Not yet recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Wake Forest Baptist Health Comprehensive Cancer Center

    Winston-Salem, North Carolina · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.